Slide
Together we are
Attend an event
Make a donation
Slide
Together we are
Make a donation
Attend an event
previous arrow
next arrow
Scientists in laboratory conducting research to cure breast cancer
Couple embracing and smiling

Alone we go faster, together we go further!

Patients are at the heart of our research

The Breast International Group’s research is supported in part by BIG against breast cancer, BIG’s the philanthropic unit. The funds raised by BIG against breast cancer go towards financing purely academic breast cancer trials and research conducted under the BIG umbrella. There are many areas of research that hold great promise for patients but have no particular interest for commercial partners. It is possible that many individual patients could be cured or otherwise benefit from a “lighter” exposure to traditional cancer treatments, for example by having the duration of their exposure to certain drugs or radiation reduced, or even eliminated altogether.

These studies hold tremendous potential for patients and promise long-term gains for society, in all regions of the world.

EXPERT - BIG radio tuning

Aims to tailor the use of radiotherapy according to each patient’s risk of breast cancer relapse, ultimately hoping to identify those patients who can safely avoid this treatment. The results of this study could influence how 2 in 5 women with breast cancer are treated in the future.

Learn more

POSITIVE - BIG time for baby

Aims to evaluate whether it is safe for women to interrupt their endocrine therapy to try to conceive after breast cancer. This has been a terrible dilemma to young women wishing to have a child. If treatment is stopped to try to conceive, will it increase the risk of cancer recurrence? This is the kind of question the study intends to address.

Learn more

AURORA - Metastatic breast cancer GPS

Aims to improve our understanding of metastatic breast cancer, to identify genetic breakdowns, and to map the routes that cancer cells take to invade other organs. Its first phase recently completed and a second is being launched to focus on specific subtypes of the disease that are particularly aggressive.

Learn more